Finally, indication for a tumor-suppressive activity of the NOTCH pathway in glioma predominantly comes from an in vivo immunocompetent setting, and a recent CRISPR screen identified frequent co-mutation of the NOTCH1 receptor and B2m, an essential component of the MHC-I antigen presentation complex [150]. This evidence concerns the gene B2M and glioma.